CIR Gives Bluebird Bio Something to Sing About: $9.3M
October 30, 2012- Share:
Gene therapy company bluebird bio has been awarded $9.3 million to continue its Phase ½ trial of a stem cell transplant therapy that could aid in the treatment of beta-thalassemia and sickle cell disease. The award came from the California Institute for Regenerative Medicine’s Strategic Partnership. Back in July, bluebird secured a hefty $60 million of Series D funding from Deerfield Partners, RA Capital, Ramius Capital Group, ARCH Venture Partners, Third Rock Ventures, TVM Capital and Forbion Capital Partners.
- Share:
-
-
-
-